Dibotermin Alfa
| 證據等級: L5 | 預測適應症: 9 個 |
目錄
Dibotermin Alfa: From Bone Regeneration to Esotropia
One-Sentence Summary
Dibotermin alfa (recombinant human BMP-2) is known for its role in inducing osteogenic differentiation and bone regeneration, and per the available evidence pack is associated with local adult bone repair use. The TxGNN model predicts it may be effective for Esotropia, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure data-driven signal with no corroborating evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bone regeneration / local adult bone repair (per repurposing rationale text; no formal indication text available — drug is not marketed in Finland) |
| Predicted New Indication | Esotropia |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| Finland Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on the information available in this evidence pack, dibotermin alfa is a recombinant human bone morphogenetic protein (BMP-2), with a known action of inducing osteogenic differentiation and bone regeneration; it has been associated with local adult bone repair applications.
Esotropia is a form of strabismus driven by extraocular muscle tone imbalance and neuromuscular control — a biological domain unrelated to osteoinduction. The evidence pack's own mechanistic assessment explicitly states that no pathway evidence links BMP-2 signaling to extraocular muscle tone regulation or strabismus, and characterizes the high TxGNN score as a purely data-driven (embedding-space) association rather than a mechanistically supported one.
Given the absence of any mechanistic rationale, clinical trials, or literature, this prediction should be treated as a low-plausibility, hypothesis-generating signal only, not a candidate for near-term clinical evaluation.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Finland Market Information
Dibotermin alfa is currently not marketed in Finland (0 authorizations on record); no product/license information is available.
Safety Considerations
Please refer to the package insert for safety information.
(Note: a Blocking-severity data gap exists — TFDA/official package insert warnings and contraindications have not yet been retrieved, which precludes a formal S1 safety pre-assessment.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top predicted indication (esotropia) has no supporting clinical trials or literature, and the evidence pack's own mechanistic review finds no biological plausibility linking BMP-2 osteoinduction to strabismus — this is an L5, model-only signal. A Blocking-severity safety data gap (no TFDA package insert data) further precludes any safety pre-assessment.
To proceed, the following is needed:
- TFDA/official package insert data (warnings, contraindications) — currently Blocking
- Confirmed mechanism of action (MOA) documentation from DrugBank or primary literature
- Preclinical/mechanistic studies evaluating any BMP-2 signaling role in extraocular muscle or strabismus biology
- Continued monitoring of clinical trial registries and literature for emerging evidence on this or the other 8 lower-confidence predicted indications in this candidate set
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.